Abstract: Slide Presentations |


Christopher L. Carroll, MD, FCCP*; Petronella Stoltz, APRN; Craig M. Schramm, MD; Aaron R. Zucker, MD
Author and Funding Information

Connecticut Children's Medical Center, Hartford, CT


Chest. 2007;132(4_MeetingAbstracts):483a. doi:10.1378/chest.132.4_MeetingAbstracts.483a
Text Size: A A A
Published online


PURPOSE: β2-adrenergic receptor (β2-AR) agonists are the most important group of drugs used in the treatment of acute asthma exacerbations. Previous studies have found that genotypic differences in the β2-AR, particularly at amino acid positions 16 and 27, affect response to chronic and single dose β2-AR agonist therapy. Our hypothesis was that genotypic differences also contribute to response to acute β2-AR agonist treatment during acute asthma exacerbations in children.

METHODS: Children admitted to the ICU for status asthmaticus between 2002-2005 were contacted and genetic samples obtained via saliva. Children hospitalized during this period had been treated with a protocol that titrated β2-AR therapy (first nebulized, then intravenous) according to clinical asthma score. The charts of those who provided samples were retrospectively reviewed. Genotyping of the β2-AR gene was performed by restriction fragment length polymorphism.

RESULTS: Thirty-two children hospitalized in the ICU during the study period were enrolled. At amino acid position 16, thirteen children were homozygous for the Gly16 allele (Gly/Gly), seven children were homozygous for the Arg16 allele (Arg/Arg), and 12 children were heterozygous (Arg/Gly). Despite similar clinical asthma scores on admission, children with the Gly/Gly genotype had significantly shorter ICU length of stay (43 ± 25 vs. 76 ± 37 hours; p=0.01), duration of continuous albuterol therapy (3.0 ± 0.9 vs. 5.2 ± 2.0 days; p=0.002), and were significantly less likely to require IV β2-AR therapy (31% vs. 74%; p=0.02) compared to children with Arg/Arg and Arg/Gly genotypes. There was no association between polymorphisms at amino acid position 27 (Glu27Gln) and response to β2-AR therapy during acute exacerbations. Haplotype analysis was also not significant.

CONCLUSION: Children homozygous for the Gly16 allele had a more rapid response to β2-AR agonist treatment received during an acute exacerbation. A child's β2-AR genotype significantly affected the response to acute β2-AR agonist therapy.

CLINICAL IMPLICATIONS: Knowledge of a child's genotype could significantly impact treatment received for severe asthma exacerbations.

DISCLOSURE: Christopher Carroll, None.

Tuesday, October 23, 2007

2:30 PM - 4:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543